Quick Answer
Kura Oncology, Inc. reported Net Income of -$278.67 million for fiscal year 2025.
Kura Oncology, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$278.67M | -60.2% |
| 2024 | -$173.98M | -14.0% |
| 2023 | -$152.63M | -12.4% |
| 2022 | -$135.84M | -4.1% |
| 2021 | -$130.47M | -45.6% |
| 2020 | -$89.62M | -41.9% |
| 2019 | -$63.14M | -4.5% |
| 2018 | -$60.45M | -70.6% |
| 2017 | -$35.43M | -28.6% |
| 2016 | -$27.56M | -21.8% |
| 2015 | -$22.62M | -73515.5% |
| 2014 | -$30.7K | -7.4% |
| 2013 | -$28.6K | -4.7% |
| 2012 | -$27.3K | -1.0% |
| 2011 | -$27.0K | -20.7% |
| 2010 | -$22.4K | -12.0% |
| 2009 | -$20.0K | +40.5% |
| 2008 | -$33.6K | -124.5% |
| 2007 | -$15.0K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$74.12M | -36.2% | -12.1% |
| June 30, 2025 | -$66.12M | -30.1% | -15.1% |
| March 31, 2025 | -$57.43M | -16.0% | -5.6% |
| September 30, 2024 | -$54.40M | -40.9% | -7.0% |
| June 30, 2024 | -$50.84M | -36.8% | -2.6% |
| March 31, 2024 | -$49.52M | -45.4% | -28.3% |
| September 30, 2023 | -$38.60M | -8.7% | -3.8% |
| June 30, 2023 | -$37.17M | -6.9% | -9.1% |
- Kura Oncology, Inc. showed a decrease of -60.2% in Net Income compared to the prior fiscal year.
- Over the 2007–2025 period, Kura Oncology, Inc.’s net income has declined by 1860526.3% (from -$15.0 thousand to -$278.67 million).
- The most recent figure is from Kura Oncology, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: